TNFRSF8 and anaplastic large cell lymphoma: Two successful cases in treating refectory ENKTL with brentuximab vedotin have been reported with relatively low CD30-positive rate (nearly 30%) compared with cHL and ALCL (usually more than 90%) [12, 38].